AnimaBiotech
Translation Control Therapeutics, the first platform for the discovery of small molecule drugs that control mRNA translation
Translation Control Discovery Platform
Breakthrough Biology
Cloud Architecture
Proprietary Analysis
A new strategy against hard and undruggable targets
Specifically decrease or increase the production of target proteins
Translation Control Lab
Anima’s Translation Control Lab (TCL) is purpose-built for the discovery of translation modulators by integrating our proprietary technologies in biology, bioinformatics, big data image analysis and cloud software architecture
Anima Lab
Cloud
• Analysis Assessment
• Bio Data Analysis
Product Pipeline
Our pipeline programs are in Fibrosis (Collagen type I translation inhibitors), RSV (inhibiting the production of viral proteins by host cell ribosomes), Oncology (C-Myc translation inhibitors) and Huntington’s Disease (monitoring mutant Huntingtin translation pausing).
Pharma Collaborations
$30 million in upfront payments, $14 million in research funding, up to $1.05 billion in milestones and low to mid single-digit tiered royalties on sales of any Lilly products resulting from the collaboration.
For partnering inquiries, please contact partnering@animabiotech.com.
17 Scientific Collaborations
14 Publications
-
A heterogeneous tRNA granule structure exhibiting rapid, bi-directional neuritictransport
Eur J Cell Biol (2018) ; 97 : 168-179. -
Monitoring protein synthesis in single live cancer cells
Integr Biol (2016); 8 :645-53 -
DSCR1 is required for both axonal growth cone extension and steering
J Cell Biol. 2016; 23;213(4):451-62. -
In vivo single-RNA tracking shows that most tRNA diffuses freely in live bacteria
Nucleic Acid Res. (2017); 45 :926-937
Coverage
News & Events
-
BIO Investor Forum
When: Oct. 22nd, 2019 - Oct. 23rd, 2019
Where: San Francisco, USAAnima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2019 BIO Investor Forum.
The BIO Investor Forum is an international biotech investor conference focused on investment trends and opportunities in life sciences, with unbiased emphasis on venture-stage growth and emerging public companies as well as those poised to join the growth “watch list” in 2020. The event features plenary sessions, business roundtables and therapeutic workshops, company presentations, and BIO One-on-One Partnering™ meetings.
-
BioJapan 2019
When: Oct. 9th, 2019 - Oct. 11th, 2019
Where: Yokohama, JapanAnima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 2019 BioJapan World Business Forum.
BioJapan is Asia’s premier partnering event for the global biotechnology industry. BioJapan has been influential in furthering interaction between Japanese and global companies and advancing new business opportunities for nearly two decades. BioJapan draws in top business development, licensing, alliance management professionals, R&D personnel, and biotech company executives from around the world.
-
19th Annual Biotech in Europe Forum Hosted by Sachs Associates
When: Sep. 25th, 2019 - Sep. 26th, 2019
Where: Basel, SwitzerlandAnima Biotech has been invited to present an overview of its Translation Control Therapeutics Platform for the discovery of small molecule drugs that control mRNA translation during the 19th Annual Biotech in Europe Forum hosted by Sachs Associates. Yochi Slonim, Co-founder and Chief Executive Offer of Anima Biotech, will also participate on a “Platform Technologies & Novel Therapeutics” panel.
The Biotech in Europe Forum is the leading international stage for those interested in investing and partnering in the biotech industry. This event unites companies of all stages with leading investors, analysts, money managers and pharma licensing executives. Sachs estimates over 700 delegates and over 100 presenting companies, and 30+ pitches by seed companies.